Clinical Trial Update: Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating metabolic changes in prostate cancer bone metastases using 68Ga-HBED-CC-PSMA PET/CT after Radium-223 therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Sir Mortimer B. Davis - Jewish General Hospital | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED